GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000646920 | Esophagus | ESCC | negative regulation of protein kinase activity | 140/8552 | 212/18723 | 1.53e-09 | 3.56e-08 | 140 |
GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
GO:0052126111 | Esophagus | ESCC | movement in host environment | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
GO:00065136 | Esophagus | ESCC | protein monoubiquitination | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:003010018 | Esophagus | ESCC | regulation of endocytosis | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
GO:003139816 | Esophagus | ESCC | positive regulation of protein ubiquitination | 82/8552 | 119/18723 | 2.41e-07 | 3.64e-06 | 82 |
GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
GO:0071453110 | Esophagus | ESCC | cellular response to oxygen levels | 114/8552 | 177/18723 | 3.63e-07 | 5.06e-06 | 114 |
GO:0036294110 | Esophagus | ESCC | cellular response to decreased oxygen levels | 105/8552 | 161/18723 | 4.20e-07 | 5.73e-06 | 105 |
GO:004206027 | Esophagus | ESCC | wound healing | 243/8552 | 422/18723 | 4.62e-07 | 6.25e-06 | 243 |
GO:003812718 | Esophagus | ESCC | ERBB signaling pathway | 82/8552 | 121/18723 | 7.23e-07 | 9.40e-06 | 82 |
GO:004580718 | Esophagus | ESCC | positive regulation of endocytosis | 69/8552 | 100/18723 | 1.97e-06 | 2.29e-05 | 69 |
GO:1901214111 | Esophagus | ESCC | regulation of neuron death | 186/8552 | 319/18723 | 3.35e-06 | 3.73e-05 | 186 |
GO:000717318 | Esophagus | ESCC | epidermal growth factor receptor signaling pathway | 73/8552 | 108/18723 | 3.36e-06 | 3.73e-05 | 73 |
GO:007084919 | Esophagus | ESCC | response to epidermal growth factor | 38/8552 | 49/18723 | 5.24e-06 | 5.49e-05 | 38 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0510039 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05100114 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa05205112 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBL | SNV | Missense_Mutation | rs759585425 | c.1028N>A | p.Arg343Gln | p.R343Q | P22681 | protein_coding | tolerated(0.07) | possibly_damaging(0.68) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.397N>C | p.Phe133Leu | p.F133L | P22681 | protein_coding | tolerated(0.22) | probably_damaging(1) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.293N>C | p.Ile98Thr | p.I98T | P22681 | protein_coding | deleterious(0.02) | benign(0.422) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CBL | SNV | Missense_Mutation | novel | c.1501N>C | p.Asp501His | p.D501H | P22681 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CBL | SNV | Missense_Mutation | | c.1619N>C | p.Arg540Pro | p.R540P | P22681 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.997) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CBL | deletion | Frame_Shift_Del | novel | c.2287delN | p.Gly763ValfsTer103 | p.G763Vfs*103 | P22681 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CBL | SNV | Missense_Mutation | novel | c.570N>C | p.Trp190Cys | p.W190C | P22681 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CBL | SNV | Missense_Mutation | | c.1366N>A | p.Asp456Asn | p.D456N | P22681 | protein_coding | deleterious(0) | benign(0.439) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.416N>T | p.Arg139Ile | p.R139I | P22681 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.617N>A | p.Arg206Gln | p.R206Q | P22681 | protein_coding | tolerated(0.09) | probably_damaging(0.978) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Fasudil | FASUDIL | 26177294 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | ANTISENSE OLIGONUCLEOTIDES | | 8849724 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Gemcitabine | GEMCITABINE | 25348515 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | 23696637 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | SU11274 | | 28835699 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | N/A | | 26230957,23690417,19901108 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Quizartinib | QUIZARTINIB | 22990016 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | IL-2 | ALDESLEUKIN | 9461587 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Erlotinib | ERLOTINIB | 25348515 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | FLT3-LIGAND | | 17446348 |